company background image
NBY

NovaBay Pharmaceuticals NYSEAM:NBY Stock Report

Last Price

US$0.11

Market Cap

US$7.2m

7D

1.2%

1Y

-80.9%

Updated

03 Oct, 2022

Data

Company Financials +
NBY fundamental analysis
Snowflake Score
Valuation3/6
Future Growth5/6
Past Performance0/6
Financial Health6/6
Dividends0/6

NBY Stock Overview

NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops and sells eyecare and skincare products in the United States and internationally.

NovaBay Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for NovaBay Pharmaceuticals
Historical stock prices
Current Share PriceUS$0.11
52 Week HighUS$0.63
52 Week LowUS$0.10
Beta2.78
1 Month Change-51.92%
3 Month Change-61.62%
1 Year Change-80.92%
3 Year Change-81.59%
5 Year Change-97.56%
Change since IPO-99.88%

Recent News & Updates

Shareholder Returns

NBYUS PharmaceuticalsUS Market
7D1.2%1.2%1.0%
1Y-80.9%4.4%-20.0%

Return vs Industry: NBY underperformed the US Pharmaceuticals industry which returned 3.2% over the past year.

Return vs Market: NBY underperformed the US Market which returned -23.2% over the past year.

Price Volatility

Is NBY's price volatile compared to industry and market?
NBY volatility
NBY Average Weekly Movement12.5%
Pharmaceuticals Industry Average Movement11.2%
Market Average Movement6.8%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market2.8%

Stable Share Price: NBY is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: NBY's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
200030Justin Hallhttps://novabay.com

NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops and sells eyecare and skincare products in the United States and internationally. It offers Avenova, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, SPF, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand.

NovaBay Pharmaceuticals, Inc. Fundamentals Summary

How do NovaBay Pharmaceuticals's earnings and revenue compare to its market cap?
NBY fundamental statistics
Market CapUS$7.23m
Earnings (TTM)-US$5.45m
Revenue (TTM)US$10.16m

0.7x

P/S Ratio

-1.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
NBY income statement (TTM)
RevenueUS$10.16m
Cost of RevenueUS$4.32m
Gross ProfitUS$5.84m
Other ExpensesUS$11.29m
Earnings-US$5.45m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.084
Gross Margin57.51%
Net Profit Margin-53.65%
Debt/Equity Ratio0%

How did NBY perform over the long term?

See historical performance and comparison